The dominant left ventricular assist device: lessons from an era

Area of Science:

• Cardiovascular Surgery
• Medical Device Technology
• Clinical Evidence

Background:

• The HeartWare ventricular assist device (VAD) era concluded, necessitating a review of its clinical data and impact.
• Fragmented data characterized the HeartWare VAD's lifespan, particularly when compared to its counterpart, the HeartMate III.
• This data scarcity limited comprehensive understanding and individualized patient care strategies.

Purpose of the Study:

• To analyze the limitations of available data from the HeartWare VAD era.
• To highlight the need for robust evidence in VAD technology.
• To advocate for randomized clinical trials for novel VADs.

Main Methods:

• Review of pertinent literature on commonly implanted durable VADs from the HeartWare era.
• Analysis of data fragmentation and its implications for clinical decision-making.
• Argument for the necessity of prospective, randomized clinical trials.

Main Results:

• The available data on the HeartWare VAD was insufficient for evidence-based practice and direct comparison.
• Incomplete understanding of device performance and patient outcomes was prevalent.
• Providers were often left to infer device superiority due to data limitations.

Conclusions:

• The cessation of HeartWare VAD production offers a critical opportunity to learn from past data limitations.
• A strong emphasis on randomized clinical trials is essential for future novel VAD development and patient care optimization.
• Future VAD research must prioritize generating high-quality, comprehensive data to ensure evidence-based clinical practice.